RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $56
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $58 to $56.
RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $58 to $56.